Home
Therapy Pipeline
- Immuno-Oncology
- Pain
Research
Team
News
About
- Contact Us
- About Us
More

Home
Therapy Pipeline
- Immuno-Oncology
- Pain
Research
Team
News
About
- Contact Us
- About Us
More

- Login
- Sign Up

product

Syntrix Pharmaceuticals > product

Sorry, there are no results to display.

Search for:

Recent Posts

Syntrix to present at 2025 Life Science Innovation Northwest (LSINW)
ASCO 2024 selects SX-682 for oral podium presentation of positive first-in-class efficacy results in patients with metastatic melanoma
New study finds SX-682 leads to “unprecedented” response and cures in pancreatic cancer models
First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
New Study Points to SX-682 as Novel Strategy to Broadly Increase the Effectiveness of Therapies Targeting the RAS/RAF/MEK/ERK Signaling Pathway in Non-Small Cell Lung Cancer

Syntrix Pharmaceuticals
215 Clay Street NW
Suite B-5
Auburn, WA 98001

©2025 All Rights Reserved

NIH Required Policy for Managing Conflicts of Significant Financial Interest

Recent Articles

Syntrix to present at 2025 Life Science Innovation Northwest (LSINW)
ASCO 2024 selects SX-682 for oral podium presentation of positive first-in-class efficacy results in patients with metastatic melanoma

Home
Team
Research
Therapy Pipeline
- Pain
- Immuno-Oncology
Apply

Get in touch

TEL: 253-833-8009
FAX: 253-833-8127 email: info@syntrixbio.com